[go: up one dir, main page]

MX378264B - Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. - Google Patents

Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Info

Publication number
MX378264B
MX378264B MX2018001499A MX2018001499A MX378264B MX 378264 B MX378264 B MX 378264B MX 2018001499 A MX2018001499 A MX 2018001499A MX 2018001499 A MX2018001499 A MX 2018001499A MX 378264 B MX378264 B MX 378264B
Authority
MX
Mexico
Prior art keywords
liquid polymer
drugs
delivery system
polymer delivery
extended administration
Prior art date
Application number
MX2018001499A
Other languages
English (en)
Other versions
MX2018001499A (es
Inventor
John Middleton
John Milton Downing
Vipin Saxena
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of MX2018001499A publication Critical patent/MX2018001499A/es
Publication of MX378264B publication Critical patent/MX378264B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Las composiciones farmacéuticas de polímero líquido con un poliéster líquido biodegradable que tiene un grupo terminal ácido carboxílico, un solvente biocompatible, y un agente farmacéutico activo, son útiles para ser administrados en el cuerpo para proveer una liberación prolongada ampliada del fármaco.
MX2018001499A 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos. MX378264B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200198P 2015-08-03 2015-08-03
US201662275407P 2016-01-06 2016-01-06
PCT/US2016/045334 WO2017024027A1 (en) 2015-08-03 2016-08-03 Liquid polymer delivery system for extended administration of drugs

Publications (2)

Publication Number Publication Date
MX2018001499A MX2018001499A (es) 2018-08-01
MX378264B true MX378264B (es) 2025-03-10

Family

ID=56684769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001499A MX378264B (es) 2015-08-03 2016-08-03 Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.

Country Status (19)

Country Link
US (3) US10786515B2 (es)
EP (2) EP3331495B1 (es)
JP (1) JP6949820B2 (es)
KR (1) KR102696721B1 (es)
CN (1) CN107920988B (es)
AU (1) AU2016302252B2 (es)
BR (1) BR112018002414B1 (es)
CA (1) CA2994704A1 (es)
DK (1) DK3331495T3 (es)
EA (1) EA036951B1 (es)
ES (2) ES2836805T3 (es)
HR (1) HRP20201991T1 (es)
HU (1) HUE052832T2 (es)
IL (1) IL257221B (es)
MX (1) MX378264B (es)
PT (1) PT3331495T (es)
TW (1) TWI718168B (es)
WO (1) WO2017024027A1 (es)
ZA (1) ZA201800591B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
BR112018002414B1 (pt) * 2015-08-03 2023-11-21 Tolmar International Limited Composição farmacêutica de polímero líquido para administração no corpo de um animal, seu uso para tratar, prover uma terapia para curar ou prevenir uma doença, distúrbio ou outra enfermidade e sistema de distribuição para administração da dita composição
EP3790574A4 (en) 2018-05-30 2022-07-13 Purdue Research Foundation TARGETING ANABOLIC DRUGS TO ACCELERATE FRACTURE REPAIR
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
WO2020065401A1 (en) 2018-09-25 2020-04-02 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
CN109966557A (zh) * 2018-12-05 2019-07-05 博志生物科技有限公司 局部缓释Abaloparatide或相关多肽的GelMA水凝胶的制备方法及应用
PL4302773T3 (pl) 2019-09-30 2025-02-10 Tolmar International Limited Ciekłe kompozycje polimerowe i systemy do przedłużonego podawania peptydów jako aktywnych składników farmaceutycznych
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法
CA3197170A1 (en) * 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
WO2024117740A1 (ko) * 2022-11-28 2024-06-06 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
TW202440148A (zh) * 2022-12-23 2024-10-16 大陸商長春金賽藥業有限責任公司 ＧｎＲＨ拮抗劑可注射組合物及其製備方法和用途
WO2024168024A1 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix organic solvent formulations
WO2024168022A2 (en) * 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6197320B1 (en) * 1994-03-11 2001-03-06 Shalaby W. Shalaby Absorbable E-caprolactone polymers and medical devices
US5668288A (en) * 1996-04-16 1997-09-16 Depuy Orthopaedics, Inc. Polyester ionomers for implant fabrication
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
AR070033A1 (es) * 2007-11-06 2010-03-10 Panacea Biotec Ltd Composiciones inyectables, sus procesos y usos
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8946277B2 (en) * 2008-04-18 2015-02-03 Warsaw Orthopedic, Inc. Clonidine formulations in a biodegradable polymer carrier
JP2012515837A (ja) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド 異なる非反復単位を有するポリマーを含むポリマー混合物、ならびにそれを作製および使用するための方法
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2012060267A1 (ja) * 2010-11-04 2012-05-10 新日鐵化学株式会社 ハードコート層付ポリカーボネート
EP2717914B1 (en) * 2011-06-10 2019-10-30 Ramscor, Inc. Sustained release formulations for delivery of proteins to the eye and methods of preparing same
CN107252498B (zh) * 2011-10-17 2021-02-19 聚合-医药有限公司 可吸收的原位凝胶形成系统、其制备方法及用途
BR112018002414B1 (pt) 2015-08-03 2023-11-21 Tolmar International Limited Composição farmacêutica de polímero líquido para administração no corpo de um animal, seu uso para tratar, prover uma terapia para curar ou prevenir uma doença, distúrbio ou outra enfermidade e sistema de distribuição para administração da dita composição

Also Published As

Publication number Publication date
HRP20201991T1 (hr) 2021-02-05
US20210060036A1 (en) 2021-03-04
BR112018002414B1 (pt) 2023-11-21
EP3804698B1 (en) 2024-01-31
US11779589B2 (en) 2023-10-10
AU2016302252A1 (en) 2018-02-22
KR102696721B1 (ko) 2024-08-19
TW201717960A (zh) 2017-06-01
US20180214459A1 (en) 2018-08-02
US10786515B2 (en) 2020-09-29
MX2018001499A (es) 2018-08-01
AU2016302252B2 (en) 2022-01-20
IL257221B (en) 2022-01-01
JP6949820B2 (ja) 2021-10-13
EA036951B1 (ru) 2021-01-19
JP2018522906A (ja) 2018-08-16
KR20180030413A (ko) 2018-03-22
CA2994704A1 (en) 2017-02-09
WO2017024027A1 (en) 2017-02-09
CN107920988A (zh) 2018-04-17
ES2975519T3 (es) 2024-07-08
EP3804698A1 (en) 2021-04-14
US20240066039A1 (en) 2024-02-29
ES2836805T3 (es) 2021-06-28
EA201890436A1 (ru) 2018-09-28
EP3331495A1 (en) 2018-06-13
BR112018002414A2 (pt) 2018-09-18
DK3331495T3 (da) 2020-12-14
TWI718168B (zh) 2021-02-11
HK1255638A1 (en) 2019-08-23
CN107920988B (zh) 2021-08-17
ZA201800591B (en) 2021-07-28
PT3331495T (pt) 2020-12-07
NZ739674A (en) 2024-10-25
EP3331495B1 (en) 2020-11-04
IL257221A (en) 2018-03-29
HUE052832T2 (hu) 2021-05-28

Similar Documents

Publication Publication Date Title
MX378264B (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.
WO2017091749A8 (en) Shape changing drug delivery devices and methods
MX2021001118A (es) Composiciones que comprenden fibras obtenidas electrohidrodinamicamente para la administracion de dosificaciones especificas de una sustancia activa a piel o mucosa.
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MX2017006653A (es) Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión.
WO2012035429A3 (en) Remotely controlled drug delivery systems
MX2015012887A (es) Composiciones de un poliortoester y un solvente aprotico.
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
EA033537B1 (ru) Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2015095624A3 (en) Drug mixing and delivery system and method
MD20160079A2 (ro) Sistem de livrare a medicamentului
AR116501A1 (es) Sistema de suministro de polímero líquido para administración extendida de drogas
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2011112996A3 (en) Injectable drug delivery system
PE20160850A1 (es) Sistema multiparticulado para administrar drogas
MX2016001607A (es) Microesferas de entecavir y composicion farmaceutica para administracion parenteral que contiene las mismas.
PE20160534A1 (es) Sistema de administracion intrauterina
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
WO2016036823A3 (en) Self-assembling drug delivery vehicles with ionically cross-linked drugs
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos
RU2726625C2 (ru) Фармацевтическая композиция, включающая полипептид
WO2016020936A3 (en) A novel oral gastroretentive pharmaceutical dosage form
EP3029059A4 (en) COMPOUND ADVERTISING PROCESSORS AND DRUG PREPARATION